Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor

Guillaume Chassagnon, Dominique Hubert, Isabelle Fajac, Pierre-Régis Burgel, Marie-Pierre Revel on behalf of the investigators
European Respiratory Journal 2016 48: 249-252; DOI: 10.1183/13993003.01918-2015
Guillaume Chassagnon
1Radiology Dept, Cochin Hospital, AP-HP, Paris, France
2Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique Hubert
2Université Paris Descartes, Sorbonne Paris Cité, Paris, France
3Pulmonary Dept and Adult CF Centre, Cochin Hospital, AP-HP, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Fajac
2Université Paris Descartes, Sorbonne Paris Cité, Paris, France
4Physiology Dept, Cochin Hospital, AP-HP, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Régis Burgel
2Université Paris Descartes, Sorbonne Paris Cité, Paris, France
3Pulmonary Dept and Adult CF Centre, Cochin Hospital, AP-HP, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Pierre Revel
1Radiology Dept, Cochin Hospital, AP-HP, Paris, France
2Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marie-pierre.revel@aphp.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In CF patients treated with ivacaftor, improvement of CT abnormalities remains stable on long-term follow-up http://ow.ly/Zxu2B

To the Editor:

Cystic fibrosis (CF) patients with gating mutations in the gene coding for the CF transmembrane conductance regulator (CFTR) protein have been the first to benefit from CFTR-targeted therapies since the approval of ivacaftor in 2012 by the Food and Drug Administration and the European Medicines Agency. Ivacaftor is a potentiator that increases chloride transport through the defective CFTR protein [1, 2]. In phase III clinical trials, ivacaftor significantly improved lung function and clinical status in patients with a G551D mutation aged ≥6 years [3, 4]. In the two studies conducted in adults and children, the forced expiratory volume in 1 s (FEV1) showed a 10.4% predicted and 12.5% pred point increase from baseline after 24 weeks of treatment, as compared to a 0.1 and 0.2% pred point decrease in the control group. Clinical efficacy of ivacaftor was also shown in patients with other gating mutations of the CFTR gene, with a 7.5% pred point increase in FEV1 after 8 weeks of treatment [5]. In all these phase III studies, the primary endpoint was the change in FEV1 and secondary endpoints were other clinical and functional parameters, such as change in weight, respiratory exacerbation rate, health status, and sweat-chloride concentration. Imaging was never listed as an endpoint. Data on computed tomography (CT) changes upon ivacaftor treatment are scarce [6–8] and long-term changes remain unknown. The aim of this study was to assess short- and long-term CT changes in adult CF patients treated with ivacaftor.

The study was approved by the Paris Ile de France I ethics committee. We conducted a multicentre retrospective study in eight French CF centres. Adult CF patients with at least one gating mutation and being treated with ivacaftor were included if they had a pre-therapeutic chest CT and at least one follow-up chest CT. Chest CT examinations were deemed eligible if they consisted in whole lung volumetric inspiratory CT acquisitions and if spirometric measurements were available within 1 month of CT examination. Chest CT examinations were performed on multidetector CT scanners, with acquisition parameters specific to each centre. CT images were reconstructed with thicknesses ranging from 0.6 to 4 mm and were visualised using the same pulmonary window settings (window width 1500, window level –450). A modified CF-CT scoring system was used, not including quantification of air trapping, since expiratory CT acquisitions were not available [9]. CT scoring was performed by one radiologist who had received 1-week intensive training in a reference centre (Lung Analysis, Erasmus Medical Center, Rotterdam, the Netherlands), in order to reach good scoring repeatability. Readings were performed in random order and the reader was blinded to patient identification, time of CT examination, results of previous CT readings and clinical data. 25 randomly selected CT scans were scored twice, with a 4-week interval, to verify intraobserver repeatability. Spirometry was performed in accordance with American Toracic Society/European Respiratory Society consensus guidelines [10]. FEV1 values expressed in percentage of predicted values were retrieved from the patient files.

Decision to perform CT as part of routine follow-up was left to the physician in charge of the patient, thus the frequency of CT examinations was not standardised. Examinations performed 3–18 months after the start of ivacaftor and those performed after 18 months of treatment were considered as short- and long-term follow-up CT examinations, respectively. FEV1 and CT scores at baseline (T0), short (T1) and long-term (T2) follow-up were compared using Wilcoxon test. Correlations between CF-CT score and FEV1, and between changes in CF-CT score and changes in FEV1 between two successive CT scans (inter-scan changes) were assessed using Spearman's correlation coefficients. Intraobserver repeatability was assessed using intraclass correlation coefficient (ICC). All analyses were performed with statistical software package “R” (version 3.2.1, R Foundation, Vienna, Austria).

22 adult patients (17 males and five females, mean±sd 36±11 years) treated with ivacaftor were included. A total of 52 CT examinations were available (22 at baseline and 30 during follow-up), and were scored with high intraobserver repeatability (ICC 0.88–0.96). Eight patients had both short- and long-term follow-up CT examinations. Results are summarised in table 1. At short-term follow-up, patients experienced a statistically significant FEV1 increase. Over the same period, CF-CT score, as well as two of its components, peribronchial thickening and mucus plugging, had significantly decreased, indicating improvement in CT scan abnormalities. At long-term follow-up and as compared to baseline, FEV1, CF-CT score, peribronchial thickening score and mucus plugging score had also significantly improved. In contrast, there was a significant increase of the bronchiectasis score (figure 1). Comparison between short- and long-term follow-up did not show any significant difference in FEV1 or CT-scores. There was a good correlation between CF-CT score and FEV1 (r= –0.73, p<0.001) and a moderate correlation between interscan changes of FEV1 and CF-CT scores (r= –0.51, p<0.001).

View this table:
  • View inline
  • View popup
TABLE 1

Results of forced expiratory volume in 1 s (FEV1) and cystic fibrosis (CF) computed tomography (CT) score

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

a) Pre-therapeutic and b) long-term (48 month) follow-up computed tomography examinations demonstrating dramatic improvement in mucus plugging under treatment with ivacaftor. Improvement in mucus plugging unmasks central (arrow) and peripheral (arrowhead) bronchiectasis leading to an increase in the bronchiectasis score of the middle lobe.

To the best of our knowledge, this study is the first to report long-term CT changes in CF patients treated with ivacaftor. It is also the largest study reporting CT changes associated with ivacaftor and the first to evaluate its effect by using the CF-CT score on the whole lung following volumetric chest CT examination. Our results show a significant improvement of CF-CT scores on both short- and long-term follow-up. This improvement is mainly related to a significant decrease of the peribronchial thickening and mucus plugging scores, which are known to represent reversible CT changes during exacerbations in CF patients [11]. Sheik et al. [8] reported similar improvement of peribronchial thickening, mucus plugging and Brody scores at 1 year follow-up in 10 patients treated with ivacaftor. However, they also found a significant decrease of the bronchiectasis score whereas we observed a significant increase of this score on long-term follow-up. This could be due to better visualisation after decrease of bronchial thickening and mucus plugging. Bronchiectasis results in irreversible changes with the destruction of elastic tissues [12]. The decrease in the bronchiectasis score reported in the study by Sheik et al. [8] might be due to under-sampling, since scoring was based on only four CT images and not on the whole lung CT acquisition. Interestingly, we found most of the CT lesion improvement occurred during the first year of treatment and remained stable on long-term follow-up, a pattern for improvement that was also reported for lung function [13]. The good correlations we report between CT scores and FEV1 suggest CT is a valuable method for monitoring changes on ivacaftor treatment. Despite being only moderate, the correlation between interscan changes of FEV1 and CF-CT score in our study was higher than that previously reported between changes of FEV1/forced vital capacity and visual score (r= –0.51 versus –0.39) [14].

Our study has several limitations. First, due to the retrospective design, CT examinations were performed at different time points and only eight patients had both short- and long-term follow-up CT examinations and there was no standardisation of the CT parameters among the centres. However, only three of the 52 CT scans had slice thicknesses >1.25 mm. The remaining consisted in high-resolution protocols. Second, we did not evaluate interobserver agreement for visual scoring, since only one radiologist could receive intensive training in a reference centre. The limited number of available trained scorers is a well-known limitation of visual CT scores [15]. Lastly, evaluating treatment efficacy with CT raises concerns about radiation dose, even though recent improvements of the CT technology allow for dramatic dose reduction.

In conclusion, our study shows that CT is a valuable method for monitoring CF patients treated with ivacaftor. Decrease of mucus plugging and peribronchial thickening occurred during the first year and remained stable on long-term follow-up, whereas bronchiectasis score slightly increased, possibly because of improved visualisation, after mucus plugging clearance.

Acknowledgements

The investigators are: Isabelle Danner-Boucher (Pulmonary Dept, G&R Laënnec Hospital, Nantes, France), Benoît Desrues (Pulmonary Dept, Pontchaillou Hospital, Rennes, France), Stéphane Dominique (Pulmonary Dept, Charles Nicolle Hospital, Rouen, France), Isabelle Durieu (Dept of Internal Medicine, Hospices Civils de Lyon et Université Claude Bernard Lyon1, Pierre-Bénite, France), Dominique Grenet (Pulmonary Dept, Foch Hospital, Suresnes, France), Anne-Cécile Henriet (Pulmonary Dept, Bretonneau Hospital, Tours, France), Anne Prevotat (Pulmonary Dept, Calmette Hospital, Lille, France).

Footnotes

  • Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

  • Received November 17, 2015.
  • Accepted March 12, 2016.
  • Copyright ©ERS 2016

References

  1. ↵
    1. Van Goor F,
    2. Hadida S,
    3. Grootenhuis PDJ, et al.
    Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106: 18825–18830.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Accurso FJ,
    2. Rowe SM,
    3. Clancy JP, et al.
    Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991–2003.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Ramsey BW,
    2. Davies J,
    3. McElvaney NG, et al.
    A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663–1672.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Davies JC,
    2. Wainwright CE,
    3. Canny GJ, et al.
    Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; 187: 1219–1225.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. De Boeck K,
    2. Munck A,
    3. Walker S, et al.
    Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 2014; 13: 674–680.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hoare S,
    2. McEvoy S,
    3. McCarthy CJ, et al.
    Ivacaftor imaging response in cystic fibrosis. Am J Respir Crit Care Med 2014; 189: 484.
    OpenUrlCrossRefPubMed
    1. Hayes D,
    2. Long FR,
    3. McCoy KS, et al.
    Improvement in bronchiectasis on CT imaging in a pediatric patient with cystic fibrosis on ivacaftor therapy. Respiration 2014; 88: 345.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Sheikh SI,
    2. Long FR,
    3. McCoy KS, et al.
    Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. J Cyst Fibros 2015; 14: 84–89.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wainwright CE,
    2. Vidmar S,
    3. Armstrong DS, et al.
    Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011; 306: 163–171.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Miller MR,
    2. Hankinson J,
    3. Brusasco V, et al.
    Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Horsley AR,
    2. Davies JC,
    3. Gray RD, et al.
    Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 2013; 68: 532–539.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Whitwell F
    . A study of the pathology and pathogenesis of bronchiectasis. Thorax 1952; 7: 213–239.
    OpenUrlFREE Full Text
  12. ↵
    1. McKone EF,
    2. Borowitz D,
    3. Drevinek P, et al.
    Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2014; 2: 902–910.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Shah RM,
    2. Sexauer W,
    3. Ostrum BJ, et al.
    High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol 1997; 169: 375–380.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Calder AD,
    2. Bush A,
    3. Brody AS, et al.
    Scoring of chest CT in children with cystic fibrosis: state of the art. Pediatr Radiol 2014; 44: 1496–1506.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 48 Issue 1 Table of Contents
European Respiratory Journal: 48 (1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor
Guillaume Chassagnon, Dominique Hubert, Isabelle Fajac, Pierre-Régis Burgel, Marie-Pierre Revel
European Respiratory Journal Jul 2016, 48 (1) 249-252; DOI: 10.1183/13993003.01918-2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor
Guillaume Chassagnon, Dominique Hubert, Isabelle Fajac, Pierre-Régis Burgel, Marie-Pierre Revel
European Respiratory Journal Jul 2016, 48 (1) 249-252; DOI: 10.1183/13993003.01918-2015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Impact of depression and anxiety on exacerbation risk in bronchiectasis
  • Respiratory management of drowning-associated ARF
  • Mitochondrial DNA as biomarker of survival in RA-ILD
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society